US › Healthcare

Silexion Therapeutics Corp (SLXN)

US · Healthcare · Biotechnology

$0.15+0.97%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.6M

EPS

$-5.17

EPS estimate

$-2.12

EPS came in at -5.17 against a street estimate of -2.12 — a miss of 143.9%.

Key statistics

Market cap

$2.2M

Forward P/E

0.0

P/B

50.44

Book value

$0.01

EPS (TTM)

$-25.49

52-week high

$32.38

52-week low

$0.14

50-day MA

$0.27

200-day MA

$6.34

Beta

-0.29

Analyst view

Analysts rate Silexion Therapeutics Corp a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $5.00.

Shareholding

Insiders

14.67%

Institutions

0.32%

Largest institutional holders

Fund	Stake
HRT FINANCIAL LLC	0.11%
UBS Group AG	0.01%
A. Montag & Associates Inc	0.00%
Royal Bank of Canada	0.00%
Pflug Koory, LLC.	0.00%
SBI Securities Co Ltd	0.00%
JONES FINANCIAL COMPANIES LLLP	0.00%
TWO SIGMA SECURITIES, LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Silexion Therapeutics Corp — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.